Short Interest in Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Declines By 98.2%

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 92 shares, a decrease of 98.2% from the January 29th total of 5,022 shares. Based on an average trading volume of 205,154 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 205,154 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Price Performance

OTCMKTS:ENZN traded down $0.02 on Wednesday, reaching $0.06. The stock had a trading volume of 131,013 shares, compared to its average volume of 74,081. Enzon Pharmaceuticals has a 12-month low of $0.03 and a 12-month high of $0.13. The firm’s fifty day moving average is $0.05 and its two-hundred day moving average is $0.06. The company has a market cap of $4.10 million, a price-to-earnings ratio of -1.11 and a beta of 0.19.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.